<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03747653</url>
  </required_header>
  <id_info>
    <org_study_id>CTR20182090</org_study_id>
    <nct_id>NCT03747653</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection</brief_title>
  <official_title>A Phase I, Multicentre, Open-label, Self-control Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaifeng Pharmaceutical (Group) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Furen Biomedical Research Institute Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaifeng Pharmaceutical (Group) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective: To assess the pharmacokinetics of Recombinant Human Coagulation Factor
      VIII-Fc fusion protein for Injection at two dose levels in patients with hemophilia A.

      Secondary objectives: To assess Safety and Tolerability by monitoring FVIII recovery and
      adverse events in patients with hemophilia A.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 8, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum measured concentration of FVIII:C (Cmax).</measure>
    <time_frame>Pre-dose and post dose of FRSW107 up to 10 days.</time_frame>
    <description>Measured by the One-stage aPTT Clotting Assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time required for the concentration of the drug to reach half of its original value (T1/2).</measure>
    <time_frame>Pre-dose and post dose of FRSW107 up to 10 days.</time_frame>
    <description>Measured by the One-stage aPTT Clotting Assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve to Infinity (AUC).</measure>
    <time_frame>Pre-dose and post dose of FRSW107 up to 10 days.</time_frame>
    <description>Measured by the One-stage aPTT Clotting Assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The measure of the efficiency of the body to remove the drug and the unit is the volume of the plasma or blood cleared of drug per unit time (CL).</measure>
    <time_frame>Pre-dose and post dose of FRSW107 up to 10 days.</time_frame>
    <description>Measured by the One-stage aPTT Clotting Assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE V5.0.</measure>
    <time_frame>Post dose of FRSW107 up to 28.</time_frame>
    <description>Adverse events related to Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection according to Common Terminology Criteria for Adverse Events (CTCAE) NCI.V5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Inhibitor.</measure>
    <time_frame>Pre-dose and post dose of FRSW107 up to 28 days.</time_frame>
    <description>Measured by the Nijmegen-Modified Bethesda Assay.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <description>Participants will receive a single intravenous (i.v.) injection of ADVATE followed by a single intravenous (i.v.) injection of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection (FRSW107) at a low dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <description>Participants will receive a single intravenous (i.v.) injection of ADVATE followed by a single intravenous (i.v.) injection of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection (FRSW107) at a high dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADVATE</intervention_name>
    <description>Patients will be administered a single dose of ADVATE.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FRSW107</intervention_name>
    <description>Patients will be administered a single dose of FRSW107 for Injection.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adolescent and Adult patients with Hemophilia A from clinical registration.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  12 years to 60 years, male.

          -  The activity of the coagulation factor VIII (FVIII:C) &lt; 2%, and previously treated
             with FVIII concentrate (s) for a minimum of 150 exposure days (EDs) prior to study
             entry.

          -  Non-immune deficiency (CD4 &gt; 200/μL).

          -  Non-acute hemorrhagic state.

          -  No history of a positive inhibitor test (&lt; 0.6 BU) or clinical signs of decreased
             response to FVIII administrations. No Family history of inhibitors.

          -  Platelet count &gt; 100,000 platelets/μL.

          -  Normal prothrombin time or INR &lt; 1.3.

          -  Normal thrombin time (TT).

          -  Normal previous results of vWF antigen examination.

          -  Negative lupus anticoagulant .

          -  Capable of understanding and willing to comply with the conditions of the protocol
             have read (patient and/or guardian).

        Exclusion Criteria:

          -  Hypersensitive to any of the excipients of the test materials (e.g. allergic to murine
             or hamster origin heterologous proteins).

          -  History of hypersensitivity or anaphylaxis associated with any FVIII or IgG2
             administration.

          -  Current FVIII inhibitor-positive or history of FVIII inhibitor-positive.

          -  Other coagulation disorder(s) in addition to hemophilia A.

          -  Infusion of any products containing FVIII within 4 days prior screening or within 72 h
             prior to administration.

          -  Patients with severe heart disease, including myocardial infarction, heart failure
             (III or higher level).

          -  Clinically significant of other systematic diseases: alcoholism, drug abuse, mental
             disorders and mental retardation.

          -  Significant hepatic or renal impairment (ALT and AST &gt; 2×ULN; serum bilirubin level &gt;
             3 × upper limit of normal (ULN) , BUN &gt; 2×ULN, Cr &gt; 2.0 mg/dL).

          -  One or more clinically significant tests for Human Immunodeficiency Virus (HIV),
             Antisyphilitic spirulina (TPHA) and Hepatitis C Virus (HCV) Antibody.

          -  Patients who received any anticoagulant or antiplatelet therapy within one week prior
             screening or need to receive an anticoagulant or antiplatelet therapy during the
             period of clinical trials.

          -  Patients having major surgery or receiving blood or bood components transfusion within
             4 weeks prior screening or having planned major surgery schedule during the study.

          -  Patients who previously participated in the other clinical trials within 1 month prior
             screening.

          -  Any life-threatening disease or condition which, according to the investigator's
             judgment, could not benefit from the trial participation.

          -  Patient who is considered by the other investigators not suitable for clinical study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Hemophilia A is an X-chromosome-linked recessive inherited bleeding disorder caused by a deficiency of coagulation factor VIII (FVIII).</gender_description>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renchi Yang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Hematology &amp; Blood Diseases Hospital Chinese Academy of Medical Sciences &amp; Peking Union Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Medical University Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangzhou</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jinan Central Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Blood Diseases Hospital Chinese Academy of Medical Sciences &amp; Peking Union Medical College</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Department, Beijing Children's Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100045</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 12, 2018</study_first_submitted>
  <study_first_submitted_qc>November 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2018</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemophilia A</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Factor VIII-Fc Fusion Protein</keyword>
  <keyword>Adolescent and Adult Patients</keyword>
  <keyword>Phase I</keyword>
  <keyword>Safety and Tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

